The global oligonucleotide synthesis market is experiencing explosive growth, projected to surge from $8.8 billion in 2024 to a staggering $19.7 billion by 2029 at a compound annual growth rate of 17.5%. This meteoric rise is fueled by several key drivers.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Driving Forces Behind the Market’s Ascent
- Escalating use of synthesized oligonucleotides in therapeutic and diagnostic applications, harnessing their potential to tackle a diverse array of neurological disorders, rare diseases, and gene therapy.
- Continuous technological advancements, such as next-generation sequencing (NGS) and the revolutionary CRISPR gene-editing tool, which are catalyzing demand for oligonucleotide synthesis.
- Burgeoning investments from governments and major industry players in life science research and synthetic biology, paving the way for groundbreaking discoveries.
- A crescendoing focus on precision and personalized medicine, underscoring the indispensable role of oligonucleotides in tailoring treatments to individual genetic profiles.
Opportunities on the Horizon
Emerging economies, such as China, India, Japan, Brazil, and Argentina, present fertile ground for market growth, attracting substantial investments from leading companies seeking to expand their footprint in these regions. For instance, in 2023, Merck KGaA, a German biotechnology giant, invested $76 million to bolster production capabilities for high-purity reagents in Nantong, China.
Challenges and Complexities
While the market’s prospects are bright, challenges persist. Achieving precise control over oligonucleotide length while minimizing impurities poses a significant hurdle. Additionally, the generation of harmful waste during synthesis is an environmental concern that demands innovative solutions. Furthermore, the efficient delivery of oligonucleotide drugs to specific targets remains a formidable obstacle, with researchers actively exploring novel strategies, such as positively charged cell-penetrating peptides, to enhance drug bioavailability.
Key Players Shaping the Landscape
Major players in the oligonucleotide synthesis market include Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific, LGC Limited, Agilent Technologies, Inc., Kaneka Corporation, Maravai Lifesciences Holdings, Inc., Azenta, Inc., Twist Bioscience Corporation, and Genscript Biotech Corporation. In the therapeutic applications segment, prominent companies include Biogen Inc., Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Astrazeneca, Astellas Pharma Inc., Jazz Pharmaceuticals Plc, Nippon Shinyaku, Co. Ltd., Ionis Pharmaceuticals, Inc., and Novartis AG.
As the oligonucleotide synthesis market continues its upward trajectory, fueled by scientific breakthroughs and a growing recognition of its transformative potential, it stands poised to reshape the landscape of therapeutics, diagnostics, and personalized medicine.
DANAHER CORPORATION (US)
Danaher is one of the key players in the oligonucleotide synthesis market. The company through its two major subsidiary Integrated DNA Technologies (IDT) and Cytiva offers various products such as predesigned and custom oligonucelotide probes, primers, as well as therapeutic oligonucleotides such as ASOs, apart from this the company provides reagents, consumables and equipments such as synthesizers for oligonucelotide synthesis. Geographically, the company operates in more than 50 countries across North America, Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva uses organic strategies such as expansions and partnerships as their key growth strategies. In 2023, Integrated DNA Technologies (IDT) opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos. In 2022, Cytiva partnered with General Biol (Anhui) Co., Ltd. a company from China to provide an integrated FlexFactory platform featuring the OligoProcess nucleic acid synthesis system, ÄKTAprocess purification system, Uniflux tangential flow filtration system, and other advanced technologies. This setup will allow General Biol (Anhui) Co., Ltd. to expand its oligonucleotide CDMO business.
THERMO FISHER SCIENTIFIC, INC. (US)
Thermo Fisher Scientific (US) held the second-largest share in the oligonucleotide synthesis market in 2023. This significant share is due to the pressnec of a strong product portfolio, including custom and predesigned primers, probes, DNA, and RNA oligos, as well as reagents and consumables. The company undertakes various organic and inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific entered in a strategic collaboration with the University of Sheffield aimed at developing workflows for the characterization and monitoring of complex oligonucleotide and mRNA products utilizing various technologies from Thermo Fisher and the research expertise of the University of Sheffield. The company also has a strong geographic presence and operates in more than 50 countries across the North America, Europe, Asia Pacific and the Latim America regions.
